14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Hold
Today BPTH ranks #9363 as hold candidate. Get a Free Stock at Robinhood
Stronger Stock

$5.17 (0.98%)

Volume: 28k

Closed: Oct 15, 2021

Hollow Logo Score: -0.205

Bio-Path Holdings Stock Forecast

$5.17 (0.98%)

Volume: 28k

Closed: Oct 15, 2021

Score Hollow Logo -0.205
Which way will BPTH go? Request
Stop-loss: $4.92 (-4.87%)
Earnings Date: Nov 11, 2021
Key Stats
Beta 0.78
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 80 ] RSI14 is 44 and the stock is currently not being overbought or oversold

Bio-Path Holdings stock upgraded from Sell Candidate to Hold/Accumulate after Friday trading session.
(Updated on Oct 15, 2021)

Hold candidate since 2021-10-15

The Bio-Path Holdings stock price gained 0.98% on the last trading day (Friday, 15th Oct 2021), rising from $5.12 to $5.17. During the day the stock fluctuated 1.96% from a day low at $5.10 to a day high of $5.20. The price has fallen in 6 of the last 10 days, but is still up by 0.19% over the past 2 weeks. Volume fell on the last day by -16 thousand shares and in total, 28 thousand shares were bought and sold for approximately $145.86 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -24.45% during the next 3 months and, with a 90% probability hold a price between $3.59 and $4.16 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, October 04, 2021, and so far it has risen 3.40%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Bio-Path Holdings stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $5.32. On a fall, the stock will find some support from the short-term average at $5.09. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.

Support, Risk & Stop-loss

Bio-Path Holdings finds support from accumulated volume at $5.16 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.10 between high and low, or 1.96%. For the last week the stock has had a daily average volatility of 2.80%.

Our recommended stop-loss: $4.92 (-4.87%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 9 days ago.)

Is Bio-Path Holdings stock A Buy?

Bio-Path Holdings holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold/Accumulate candidate.

Current score: -0.205

Predicted Opening Price for Bio-Path Holdings of Monday, October 18, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price October 18, 2021 Current price
$5.16 $5.17 (Overvalued)
Hold/Accumulate Upgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

HC Wainwright is very positive about BPTH and gave it a "Buy" rating on Apr 13, 2021. The price target was set to $12.00.

Volatility and Risk
Daily Average Volatility: 2.80 %
Overall Risk: Very High High Medium Low Very Low
2.80 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $5.56
Price: $5.17
Support: $5.16

BPTH Insider Trading Show all Trades



Last 61 transactions
Buy: 9 471 808 | Sell: 114 457 (Shares)
Date Action Amount Person Type
Jun 16, 2020 Buy 85 000 Nielsen Peter Henry Common Stock Option (right to buy)
Mar 27, 2020 Buy 10 000 Molsbergen Tamaro Martina Common Stock Option (right to buy)
Mar 27, 2020 Buy 10 000 Aubert Paul Common Stock Option (right to buy)
Mar 27, 2020 Buy 10 000 Cleaver Heath Common Stock Option (right to buy)
Mar 27, 2020 Buy 10 000 Morris Douglas P Common Stock Option (right to buy)
Show all Insider Trades


Last 61 transactions
Buy: 9 471 808 | Sell: 114 457 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 5.26 1.68 %
5.22 0.94 %
5.19 0.48 %
Current price: 5.17
Support 5.12 -1.00 %
5.09 -1.45 %
5.06 -2.19 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 5.83 12.77 %
5.78 11.80 %
5.56 7.54 %
Current price 5.17
Support 5.16 -0.19%
5.15 -0.39%
5.00 -3.29%

Click to get the best stock tips daily for free!

About Bio-Path Holdings

Bio-Path Holdings Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is Liposomal Grb2, which is in Phase II clinical trials for the t... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE